MLchartDataset catalogue

Arzerra

Term · Oncology and biomedicine · MLC-T-ONC-000738

A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. Arzerra binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Arzerra may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called HuMax-CD20 and ofatumumab.

Table 1. Record
IdentifierMLC-T-ONC-000738
FieldOncology and biomedicine
SynonymsHuMax-CD20; ofatumumab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-000738",
  "term": "Arzerra",
  "field": "Oncology and biomedicine",
  "definition": "A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. Arzerra binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Arzerra may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called HuMax-CD20 and ofatumumab.",
  "synonyms": [
    "HuMax-CD20",
    "ofatumumab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/arzerra/"
}

Record 2,472 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.